Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses Are Associated with Decreased Relapse Rates

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 4, 2008, Pages 449-457

  Nakamura, Ryotaro ^a   Auayporn, Nademanee ^a   Smith, David D ^a   Palmer, Joycelynne ^a   Sun, Joel Y ^a   Schriber, Jeffrey ^b   Pullarkat, Vinod ^a   Parker, Pablo ^a   Rodriguez, Roberto ^a   Stein, Anthony ^a   Rosenthal, Joseph ^a   Wang, Shirong ^a   Karanas, Chatchada ^a   Gaal, Karl ^a   Senitzer, David ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b City of Hope/Samaritan Bone Marrow Transplant Program   (United States)

Author keywords

CD34+ cell dose; Peripheral blood hematopoietic cell transplantation; Unrelated donor

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CD34 SELECTION; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NATURAL KILLER CELL; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNITED STATES; UNIVARIATE ANALYSIS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD34; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HUMANS; INFANT; LEUKEMIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 40649101217     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.02.005     Document Type: Article

References (34)

1. Mavroudis D., Read E., Cottler-Fox M., et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 88 (1996) 3223-3229
2. Nakamura R., Bahceci E., Read E.J., et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 115 (2001) 95-104
3. Ringden O., Barrett A.J., Zhang M.J., et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 121 (2003) 874-885
4. Dominietto A., Lamparelli T., Raiola A.M., et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 100 (2002) 3930-3934
5. Sierra J., Storer B., Hansen J.A., et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 89 (1997) 4226-4235
6. Bittencourt H., Rocha V., Chevret S., et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 99 (2002) 2726-2733
7. Perez-Simon J.A., Diez-Campelo M., Martino R., et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 102 (2003) 1108-1113
8. Gorin N.C., Labopin M., Boiron J.M., et al. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond-The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 24 (2006) 3959-3966
9. Przepiorka D., Smith T.L., Folloder J., et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 94 (1999) 1465-1470
10. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98 (2001) 3221-3227
11. Mohty M., Bilger K., Jourdan E., et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 17 (2003) 869-875
12. Remberger M., Ringden O., Blau I.-W., et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 98 (2001) 1739-1745
13. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
14. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819
15. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants: killer immunoglobulin-like receptor. Blood 100 (2002) 3825-3827
16. Miller J.S., Cooley S., Parham P., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109 (2007) 5058-5061
17. Savani B.N., Rezvani K., Mielke S., et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107 (2006) 1688-1695
18. Schaffer M., and Olerup O. HLA-AB typing by polymerase-chain reaction with sequence-specific primers: more accurate, less errors, and increased resolution compared to serological typing. Tissue Antigens 58 (2001) 299-307
19. Sun J.Y., Gaidulis L., Miller M.M., et al. Development of a multiplex PCR-SSP method for Killer-cell immunoglobulin-like receptor genotyping. Tissue Antigens 64 (2004) 462-468
20. Beelen D.W., Ottinger H., Ferencik S., et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105 (2005) 2594-2600
21. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105 (2005) 4878-4884
22. Blume K.G., Forman S.J., and Appelbaum F.R. Thomas' Hematopoietic Cell Transplantation. 3rd ed. (2004), Blackwell Scientific Publications, Malden, MA
23. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
24. Shulman H.M. Graft-versus-host disease. Surv Synth Pathol Res 3 (1984) 233-234
25. Kaplan G., and Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
26. Peto R., and Peto J. Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 135 (1972) 195-206
27. Hauck W.W., and Donner A. Wald's test as applied to hypotheses in logit analysis. J Am Stat Assoc 72 (1977) 851-853
28. Cox D.R. Regression models and life tables. J R Stat Soc B 34 (1972) 187-220
29. Jiang Y.Z., Barrett A.J., Goldman J.M., and Mavroudis D.A. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus host disease following allogeneic bone marrow transplantation. Ann Hematol 74 (1997) 1-6
30. Niederwieser D., Gastl G., Rumpold H., Marth C., Kraft D., and Huber C. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol 65 (1987) 301-305
31. Boyington J.C., and Sun P.D. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol 38 (2002) 1007-1021
32. Gumperz J.E., Litwin V., Phillips J.H., Lanier L.L., and Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181 (1995) 1133-1144
33. Gumperz J.E., Barber L.D., Valiante N.M., et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol 158 (1997) 5237-5241
34. Kim D.H., Kim J.G., Sohn S.K., et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 125 (2004) 217-224